Scarica l'app Stockscreener
5.28
3.13%
0.16
Codexis Inc Borsa (CDXS) Ultime notizie
BNP Paribas Financial Markets Trims Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution - Investing.com India
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution By Investing.com - Investing.com South Africa
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - Yahoo Finance
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way? - Simply Wall St
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Announces New Employment Inducement Grants - The Manila Times
Codexis Awards Strategic Equity Package: 208K Shares in Options and RSUs for Key New Hires - StockTitan
Codexis stock soars to 52-week high, touches $4.92 By Investing.com - Investing.com Canada
Codexis stock soars to 52-week high, touches $4.92 - Investing.com India
Global Artificial Sweeteners Market to Observe Growth at a CAGR of ~4% by 2030 | DelveInsight - GlobeNewswire Inc.
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Fred Alger Management LLC - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Sees Large Decrease in Short Interest - MarketBeat
Cantor Fitzgerald Reaffirms “Overweight” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzymatic platform poised to shake up RNAi stock - Investing.com
Codexis (NASDAQ:CDXS) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
GSA Capital Partners LLP Grows Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings) - Benzinga
Codexis (STU:4QK) EBITDA per Share : €-0.40 (TTM As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) 3-Year FCF Growth Rate : -35.00% (As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Codexis to Present at Piper Sandler Healthcare Conference in December 2024 | CDXS Stock News - StockTitan
Codexis (NASDAQ:CDXS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewswire
Codexis Achieves 98% Efficiency in Breakthrough siRNA Synthesis Platform | CDXS Stock News - StockTitan
Baillie Gifford & Co. Sells 895,002 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - The Manila Times
Codexis adds biotech veteran Raymond De Vré to board - Investing.com India
Codexis Strengthens Board and Updates Bylaws - TipRanks
CDXSCodexis, Inc. Latest Stock News & Market Updates - StockTitan
Codexis adds biotech veteran Raymond De Vré to board By Investing.com - Investing.com UK
Codexis Strengthens Board with Biotech Veteran Raymond De Vré, Former PolyPeptide CEO | CDXS Stock News - StockTitan
Biofuel Enzymes Market Growth Surge: Key Players and Market - openPR
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewswire
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for - The Bakersfield Californian
Codexis to Showcase Breakthrough RNA Platform, Partners with Bachem at TIDES Europe 2024 | CDXS Stock News - StockTitan
Codexis (CDXS) Grants New Employee 50,000 Stock Options, 15,000 RSUs in Equity Package - StockTitan
Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors - Simply Wall St
Benchmark Downgrades Codexis (CDXS) - MSN
CDXS (Codexis) PE Ratio : At Loss (As of Nov. 06, 2024) - GuruFocus.com
Codexis (FRA:4QK) 3-Year EBITDA Growth Rate : -26.40% (As of Sep. 2024) - GuruFocus.com
Benchmark Reaffirms “Hold” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock By Investing.com - Investing.com Australia
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):